 |
|
|
| |
SAFETY AND EFFICACY OF THE COMBINATION DACLATASVIR-SOFOSBUVIR IN HCV GENOTYPE 1-MONO-INFECTED PATIENTS FROM THE FRENCH OBSERVATIONAL COHORT ANRS CO22 HEPATHER
|
| |
| |
from Jules: by looking at Base Line characteristics in tables below: 18% had diabetes, 78% had cirrhosis, 31% hypertension, 9% decompensated cirrhosis, 50% Gt1a/44% Gt1b, 34% wit platelet counts <100,000, 10% with ALT>5x ULN..... with 12 or 24 weeks DCV/Sof/Rbv 97-100% achieved SVR.
Reported by Jules Levin
EASL 2015 April 22-26 Vienna Austria
Stanislas POL, Marc BOURLIERE, Sandy LUCIER, Victor DE LEDINGHEN, Fabien ZOULIM, Celine DORIVAL-MOULY, Sophie METIVIER, Dominique LARREY, Albert TRAN, Christophe HEZODE, Jean-Pierre BRONOWICKI, Didier SAMUEL, Patrick MARCELLIN, Jean-Pierre ZARSKI, Anne MINELLO, Laurent ALRIC, Jean-Claude TRINCHET, Pierre NAHON, Dominique GUYADER, Olivier CHAZOUILLERES, Ghassan RIACHI, Veronique LOUSTAUD-RATTI, Xavier CAUSSE, Philippe MATHURIN, Isabelle HUBERT-FOUCHARD, Isabelle ROSA, Yves BENHAMOU, Jerome GOURNAY, Jean-Jacques RAABE, François RAFFI, Ventzislava PETROV-SANCHEZ, Alpha DIALLO, Helène FONTAINE, Fabrice CARRAT on the behalf of the ANRS/AFEF HEPATHER study group
|
| |
|
|
|
|
|
